Pacira BioSciences (PCRX) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 9, 2026, with shareholders voting on board nominees amid a contested proxy contest with DOMA Perpetual Capital Management.

• Company highlights strong operational progress and stock performance, with shares up over 35% since launching the 5x30 strategy.

• 5x30 strategy focuses on five pillars: patients served, product revenue, profitability, pipeline advancement, and partnerships, targeting durable growth through 2030.

• Returned $150 million to shareholders in 2025 and $50 million in 2026 via share repurchases, reducing outstanding shares from 47 million to 39 million.

Voting matters and shareholder proposals

• Shareholders are urged to vote for three board nominees—Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans—on the BLUE proxy card.

• Board strongly opposes DOMA’s three nominees, citing lack of public company and biopharmaceutical experience.

• Board recommends voting against DOMA’s nominees due to concerns over conflicts of interest and lack of relevant expertise.

Board of directors and corporate governance

• Board refreshed with five new independent directors since October 2023, with a sixth nominated for election.

• Board composition includes expertise in executive leadership, M&A, R&D, operations, commercialization, and supply chain.

• Board separated Chair and CEO roles in January 2024 to enhance accountability.

• Bylaws amended to adopt majority voting for uncontested director elections and plurality for contested elections.

• Board regularly engages with shareholders, including 17 meetings with DOMA since September 2023.